Fig. 4: TSA treatment downregulates ZEB1 protein level through stabilizing CHFR.
From: CHFR regulates chemoresistance in triple-negative breast cancer through destabilizing ZEB1
a, b Full-length MYC-CHFR, MYC-CHFR∆FHA, MYC-CHFR∆RING, MYC-CHFR∆CRD, and MYC-GFP were transiently transfected into HEK293T cells and then treated with 1 μM TSA for 36 h and immunoblotted with the MYC antibody. SE: short exposure, LE: long exposure (a); cells were also treated with 1 μM SAHA for 36 h and immunoblotted with the MYC antibody (b). c MYC-CHFR was transfected into HEK293T cells, pretreated with or without SAHA for 6 h, treated with 1 μM TSA or SAHA as indicated for 36 h, and then immunoblotted with the MYC, Acetyl-H3, and β-actin antibodies. d, e SUM159 and BT549 cells were treated with 1 μM TSA for 36 h and immunoblotted with the CHFR, ZEB1, and β-actin antibodies. f, g LM2 and BT549 cells that stably knocked down CHFR were treated with 1 μM TSA for 36 h and immunoblotted with the ZEB1 and β-actin antibodies. h LM2 cells that stably knocked down ZEB1 were treated with 1 μM TSA for 36 h and immunoblotted with the FASN and β-actin antibodies.
